Catalyst Pharmaceuticals (CPRX) Competitors

$31.28 +0.00 (+0.01%)

As of 12:03 PM Eastern

CPRX vs. ASND, SMMT, BBIO, AXSM, and ELAN

Should you buy Catalyst Pharmaceuticals stock or one of its competitors? MarketBeat compares Catalyst Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Catalyst Pharmaceuticals include Ascendis Pharma A/S (ASND), Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

How does Catalyst Pharmaceuticals compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Ascendis Pharma A/S has a net margin of 57.87% compared to Catalyst Pharmaceuticals' net margin of 37.08%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Ascendis Pharma A/S has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Catalyst Pharmaceuticals has lower revenue, but higher earnings than Ascendis Pharma A/S. Catalyst Pharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	16.95	-$258M	$8.67	25.53
Catalyst Pharmaceuticals	$596.96M	6.41	$214.33M	$1.74	17.98

Ascendis Pharma A/S currently has a consensus price target of $295.39, indicating a potential upside of 33.43%. Catalyst Pharmaceuticals has a consensus price target of $32.00, indicating a potential upside of 2.29%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, research analysts clearly believe Ascendis Pharma A/S is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

In the previous week, Ascendis Pharma A/S had 6 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 6 mentions for Ascendis Pharma A/S and 0 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.44 beat Ascendis Pharma A/S's score of 1.34 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Ascendis Pharma A/S	Positive
Catalyst Pharmaceuticals	Positive

Summary

Ascendis Pharma A/S beats Catalyst Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Catalyst Pharmaceuticals compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

Catalyst Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Catalyst Pharmaceuticals	$596.96M	6.41	$214.33M	$1.74	17.98

Summit Therapeutics presently has a consensus price target of $26.05, suggesting a potential upside of 76.50%. Catalyst Pharmaceuticals has a consensus price target of $32.00, suggesting a potential upside of 2.29%. Given Summit Therapeutics' higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by company insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Summit Therapeutics had 7 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 7 mentions for Summit Therapeutics and 0 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.44 beat Summit Therapeutics' score of 0.39 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Summit Therapeutics	Neutral
Catalyst Pharmaceuticals	Positive

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Summit Therapeutics' net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

Summit Therapeutics has a beta of -1.32, suggesting that its stock price is 232% less volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Summary

Catalyst Pharmaceuticals beats Summit Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Catalyst Pharmaceuticals compare to BridgeBio Pharma?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, BridgeBio Pharma had 6 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 6 mentions for BridgeBio Pharma and 0 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.44 beat BridgeBio Pharma's score of 1.00 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Catalyst Pharmaceuticals	Positive
BridgeBio Pharma	Positive

Catalyst Pharmaceuticals presently has a consensus target price of $32.00, suggesting a potential upside of 2.29%. BridgeBio Pharma has a consensus target price of $89.59, suggesting a potential upside of 32.18%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.85

Catalyst Pharmaceuticals has a net margin of 37.08% compared to BridgeBio Pharma's net margin of -124.42%. Catalyst Pharmaceuticals' return on equity of 35.76% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Catalyst Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$596.96M	6.41	$214.33M	$1.74	17.98
BridgeBio Pharma	$502.08M	26.44	-$724.93M	-$3.74	N/A

Catalyst Pharmaceuticals has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

Summary

Catalyst Pharmaceuticals beats BridgeBio Pharma on 9 of the 17 factors compared between the two stocks.

How does Catalyst Pharmaceuticals compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Axsome Therapeutics currently has a consensus price target of $251.26, suggesting a potential upside of 6.70%. Catalyst Pharmaceuticals has a consensus price target of $32.00, suggesting a potential upside of 2.29%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

In the previous week, Axsome Therapeutics had 14 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 14 mentions for Axsome Therapeutics and 0 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.44 beat Axsome Therapeutics' score of 0.32 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Axsome Therapeutics	Neutral
Catalyst Pharmaceuticals	Positive

Axsome Therapeutics has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by company insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Axsome Therapeutics' net margin of -26.59%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

Catalyst Pharmaceuticals has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	18.98	-$183.17M	-$3.73	N/A
Catalyst Pharmaceuticals	$596.96M	6.41	$214.33M	$1.74	17.98

Summary

Catalyst Pharmaceuticals beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Catalyst Pharmaceuticals compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

In the previous week, Elanco Animal Health had 13 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 13 mentions for Elanco Animal Health and 0 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.44 beat Elanco Animal Health's score of 1.08 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Elanco Animal Health	Positive
Catalyst Pharmaceuticals	Positive

Catalyst Pharmaceuticals has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.67	-$232M	-$0.50	N/A
Catalyst Pharmaceuticals	$596.96M	6.41	$214.33M	$1.74	17.98

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Elanco Animal Health's net margin of -4.95%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

Elanco Animal Health has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by company insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Elanco Animal Health currently has a consensus price target of $28.20, suggesting a potential upside of 11.73%. Catalyst Pharmaceuticals has a consensus price target of $32.00, suggesting a potential upside of 2.29%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, equities research analysts clearly believe Elanco Animal Health is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

Summary

Catalyst Pharmaceuticals beats Elanco Animal Health on 10 of the 17 factors compared between the two stocks.

Get Catalyst Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPRX vs. The Competition

Export

Metric	Catalyst Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.83B	$2.97B	$6.45B	$12.42B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	17.98	18.16	23.89	24.35
Price / Sales	6.41	310.02	524.38	119.30
Price / Cash	10.70	55.72	41.27	57.13
Price / Book	4.03	3.96	10.06	6.74
Net Income	$214.33M	$75.85M	$3.56B	$337.03M
7 Day Performance	-0.02%	-1.32%	-0.60%	0.24%
1 Month Performance	N/A	N/A	N/A	-1.60%
1 Year Performance	23.70%	23.82%	29.29%	34.04%

Catalyst Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPRX Catalyst Pharmaceuticals	4.2055 of 5 stars	$31.28 +0.0%	$32.00 +2.3%	+25.6%	$3.83B	$596.96M	17.98	80	Negative News
ASND Ascendis Pharma A/S	4.6288 of 5 stars	$218.82 -2.4%	$295.39 +35.0%	+24.3%	$13.98B	$865.78M	25.24	1,189	Positive News Short Interest Decrease
SMMT Summit Therapeutics	2.1492 of 5 stars	$15.71 -10.4%	$26.05 +65.8%	-26.9%	$13.61B	N/A	N/A	110	Analyst Forecast High Trading Volume
BBIO BridgeBio Pharma	3.5665 of 5 stars	$65.36 -1.4%	$88.90 +36.0%	+74.5%	$12.98B	$502.08M	N/A	400	Positive News Analyst Forecast High Trading Volume
AXSM Axsome Therapeutics	2.3237 of 5 stars	$230.25 -1.8%	$251.26 +9.1%	+111.9%	$12.07B	$638.50M	N/A	380	News Coverage Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CPRX) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Catalyst Pharmaceuticals (CPRX) Competitors

CPRX vs. ASND, SMMT, BBIO, AXSM, and ELAN

How does Catalyst Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

How does Catalyst Pharmaceuticals compare to Summit Therapeutics?

Summary

How does Catalyst Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does Catalyst Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Catalyst Pharmaceuticals compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPRX vs. The Competition

Catalyst Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Catalyst Pharmaceuticals (CPRX) Competitors

CPRX vs. ASND, SMMT, BBIO, AXSM, and ELAN

How does Catalyst Pharmaceuticals compare to Ascendis Pharma A/S?

Is ASND or CPRX more profitable?

Do insiders and institutionals believe in ASND or CPRX?

Which has more risk & volatility, ASND or CPRX?

Which has stronger earnings & valuation, ASND or CPRX?

Do analysts recommend ASND or CPRX?

Does the media favor ASND or CPRX?

Summary

How does Catalyst Pharmaceuticals compare to Summit Therapeutics?

Which has higher earnings & valuation, SMMT or CPRX?

Do analysts recommend SMMT or CPRX?

Do insiders & institutionals hold more shares of SMMT or CPRX?

Does the media refer more to SMMT or CPRX?

Is SMMT or CPRX more profitable?

Which has more risk and volatility, SMMT or CPRX?

Summary

How does Catalyst Pharmaceuticals compare to BridgeBio Pharma?

Do insiders and institutionals have more ownership in CPRX or BBIO?

Does the media favor CPRX or BBIO?

Do analysts rate CPRX or BBIO?

Is CPRX or BBIO more profitable?

Which has higher valuation and earnings, CPRX or BBIO?

Which has more risk and volatility, CPRX or BBIO?

Summary

How does Catalyst Pharmaceuticals compare to Axsome Therapeutics?

Do analysts rate AXSM or CPRX?

Does the media favor AXSM or CPRX?

Which has more volatility and risk, AXSM or CPRX?

Do institutionals & insiders hold more shares of AXSM or CPRX?

Is AXSM or CPRX more profitable?

Which has preferable earnings & valuation, AXSM or CPRX?

Summary

How does Catalyst Pharmaceuticals compare to Elanco Animal Health?

Does the media refer more to ELAN or CPRX?

Which has higher earnings and valuation, ELAN or CPRX?

Is ELAN or CPRX more profitable?

Which has more risk and volatility, ELAN or CPRX?

Do insiders and institutionals hold more shares of ELAN or CPRX?

Do analysts recommend ELAN or CPRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPRX vs. The Competition

Catalyst Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools